- Home
- BOLT vs KZIA Comparison
BOLT vs KZIA Comparison
Compare BOLT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- KZIA
- Stock Information
- Founded
- BOLT 2015
- KZIA 1994
- Country
- BOLT United States
- KZIA Australia
- Employees
- BOLT N/A
- KZIA N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- KZIA Health Care
- Exchange
- BOLT Nasdaq
- KZIA Nasdaq
- Market Cap
- BOLT 9.4M
- KZIA 9.0M
- IPO Year
- BOLT 2021
- KZIA 1999
- Fundamental
- Price
- BOLT $5.19
- KZIA $7.95
- Analyst Decision
- BOLT Buy
- KZIA Strong Buy
- Analyst Count
- BOLT 3
- KZIA 2
- Target Price
- BOLT $47.50
- KZIA $14.00
- AVG Volume (30 Days)
- BOLT 14.4K
- KZIA 19.0K
- Earning Date
- BOLT 08-14-2025
- KZIA 06-05-2025
- Dividend Yield
- BOLT N/A
- KZIA N/A
- EPS Growth
- BOLT N/A
- KZIA N/A
- EPS
- BOLT N/A
- KZIA N/A
- Revenue
- BOLT $4,167,000.00
- KZIA $1,549,158.00
- Revenue This Year
- BOLT N/A
- KZIA N/A
- Revenue Next Year
- BOLT N/A
- KZIA $49.25
- P/E Ratio
- BOLT N/A
- KZIA N/A
- Revenue Growth
- BOLT N/A
- KZIA 248983.08
- 52 Week Low
- BOLT $4.59
- KZIA $2.86
- 52 Week High
- BOLT $14.36
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- BOLT 46.64
- KZIA 49.06
- Support Level
- BOLT $4.81
- KZIA $7.69
- Resistance Level
- BOLT $5.28
- KZIA $8.39
- Average True Range (ATR)
- BOLT 0.26
- KZIA 0.65
- MACD
- BOLT 0.01
- KZIA 0.05
- Stochastic Oscillator
- BOLT 70.26
- KZIA 64.55
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.